Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic

  • Search Hotels in Pleasanton

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adicet Bio Inc (NQ: ACET )

0.9140 -0.0531 (-5.49%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 842,925
Open 0.9667
Bid (Size) 0.9116 (1)
Ask (Size) 0.9335 (20)
Prev. Close 0.9671
Today's Range 0.9116 - 0.9802
52wk Range 0.9300 - 3.770
Shares Outstanding 42,957,586
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases
From Adicet Bio, Inc.
Via Business Wire

Performance

YTD
-54.53%
-54.53%
1 Month
-38.66%
-38.66%
3 Month
-41.78%
-41.78%
6 Month
-43.93%
-43.93%
1 Year
-20.52%
-20.52%

More News

Read More
Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024
From Adicet Bio, Inc.
Via Business Wire
Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio to Participate in Upcoming Investor Conferences
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio to Present at the American Society of Gene & Cell Therapy’s (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference
From Adicet Bio, Inc.
Via Business Wire
Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases
From Adicet Bio, Inc.
Via Business Wire
ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue
From Adicet Bio, Inc.
Via Business Wire
This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday
Via Benzinga
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors
From Adicet Bio, Inc.
Via Business Wire
ACET Stock Earnings: Adicet Bio Beats EPS for Q2 2024
Via InvestorPlace
Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio to Participate in Upcoming Investor Conferences
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma
From Adicet Bio, Inc.
Via Business Wire
Under-$10 Picks: 3 Biotech Stocks That Can Double Before the End of 2024
Via InvestorPlace
Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis
From Adicet Bio, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photography by Christophe Tomatis
Copyright © 2010-2020 Pleasanton.com & California Media Partners, LLC. All rights reserved.